Logo Kérwá
 

Pros and cons of different therapeutic antibody formats for recombinant antivenom development

Simple item page
dc.creatorLaustsen, Andreas Hougaard
dc.creatorGutiérrez, José María
dc.creatorKnudsen, Cecilie
dc.creatorJohansen, Kristoffer H.
dc.creatorBermúdez Méndez, Erick
dc.creatorCerni, Felipe A.
dc.creatorJürgensen, Jonas A.
dc.creatorLedsgaard, Line
dc.creatorMartos Esteban, Andrea
dc.creatorØhlenschlæger, Mia
dc.creatorPus, Urska
dc.creatorAndersen, Mikael Rørdam
dc.creatorLomonte, Bruno
dc.creatorEngmark, Mikael Gerling
dc.creatorPucca, Manuela Berto
dc.date.accessioned2019-02-04T16:29:56Z
dc.date.available2019-02-04T16:29:56Z
dc.date.issued2018-05
dc.description.abstractAntibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.es
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiologíaes
dc.description.sponsorshipNovo Nordisk Foundation/[16OC0019248]/NNF/Dinamarcaes
dc.description.sponsorshipNovo Nordisk Foundation/[13OC0005613]/NNF/Dinamarcaes
dc.description.sponsorshipMinisterio de Ciencia, Tecnología y Telecomunicaciones/[PEM-066-2015-II]/MICITT/Costa Ricaes
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnologico/[150749/2017-1]/CNPq/Brasiles
dc.description.sponsorshipUniversidad de Costa Rica/[OAICE-CAB-05-56-2016]/UCR/Costa Ricaes
dc.identifier.citationhttps://www.sciencedirect.com/science/article/pii/S0041010118301144?via%3Dihub
dc.identifier.doihttps://doi.org/10.1016/j.toxicon.2018.03.004
dc.identifier.issn0041-0101
dc.identifier.urihttps://hdl.handle.net/10669/76544
dc.language.isoen_US
dc.rightsacceso abierto
dc.sourceToxicon, vol.146, pp. 151-175.es
dc.subjectAntivenomes
dc.subjectVenomes
dc.subjectRecombinant antivenomes
dc.subjectAntibodieses
dc.subjectSnakebitees
dc.subjectScorpion stinges
dc.subjectSpider bitees
dc.subjectAnimal envenominges
dc.subjectPharmacokineticses
dc.subjectPharmacodynamicses
dc.subjectImmunogenicityes
dc.subjectVenom neutralizationes
dc.subjectAntibody expressiones
dc.subjectAntivenom designes
dc.subjectAdverse reactionses
dc.subjectNeglected tropical diseaseses
dc.subjectBiotechnologyes
dc.subject615.946 Venenos animaleses
dc.titlePros and cons of different therapeutic antibody formats for recombinant antivenom developmentes
dc.typeartículo original

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2018_Antivenenos_Toxicon_Laustsen_recombinant_antibody_formats_Review.pdf
Size:
2.85 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.83 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Microbiología